CTOs on the Move


 
Myomo Inc is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.myomo.com
  • 529 Main St Ste 205
    Boston, MA USA 02129
  • Phone: 877.736.9666

Executives

Name Title Contact Details

Similar Companies

Almost Family

Almost Family is a leading provider of home health nursing, rehabilitation and personal care services. We are a family of companies with names you can trust. For over thirty years, we have been providing skilled compassionate home health care in our local communities. We bring our expertise into the home - the ideal setting to promote healing, comfort and support to those facing the challenges of aging. Our Senior Advocacy philosophy addresses these challenges in a revolutionary new way. Our clinical team looks beyond the obvious needs of the patient to become advocates in all dimensions of physical, mental and emotional well-being. Our goal is to promote independence, allowing seniors to age in place for as long as possible.

Wellframe

Wellframe helps healthcare organizations support people beyond the four walls of care delivery. We provide care transformation services, a patented engagement platform, clinical programs that support the clinical and social determinants of health, and rigorous measurement.

Toronto Academy of Dentistry

Toronto Academy of Dentistry is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CaroMont Health

CaroMont Health offers a full range of services to help keep your employees physically and emotionally fit. These services are provided through CaroMont Occupational Medicine, CaroMont Speakers Bureau and Gaston Memorial Hospital. Our office is located

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.